
Brazilian president Jair Bolsonaro has not filled key appointments to Brazil’s antitrust regulator (CADE), leaving the body in a state of paralysis, reported Bloomberg.
CADE, which has recently handled the Brazilian portion of high-profile mergers such as Walt Disney-Fox, was down to only three of its seven board members. In May, senior government ministers put forward names to fill in the vacancies. Early last month, Bolsonaro withdrew those appointees from Senate consideration without offering a public explanation, only to submit new suggestions a few days later.
According to Bloomberg, the reversal came right after the president announced a controversial plan to appoint his own son, Eduardo Bolsonaro, as Brazil’s ambassador to Washington, a diplomatic posting that also requires Senate approval.
The new names suggested by Bolsonaro were agreed on with senior lawmakers, including Senate President Davi Alcolumbre, according to three members of the upper house and two ex-board members of CADE, who requested anonymity to speak freely. They accused the president of using the nominations as a bargaining chip to overcome opposition to his son’s nomination.
The debate over CADE has serious business implications. Without quorum to rule on major cases, over 70 mergers are currently on hold in Brazil, according to Bloomberg.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas